Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib

  • Yoojoo Lim
  • Ji-In Bang
  • Sae-Won Han
  • Jin Chul Paeng
  • Kyung-Hun Lee
  • Jee Hyun Kim
  • Gyeong Hoon Kang
  • Seung-Yong Jeong
  • Kyu Joo Park
  • Tae-You Kim
Original Article

DOI: 10.1007/s00259-016-3577-0

Cite this article as:
Lim, Y., Bang, JI., Han, SW. et al. Eur J Nucl Med Mol Imaging (2017) 44: 757. doi:10.1007/s00259-016-3577-0

Abstract

Purpose

This study was performed to evaluate whether fluorine-18 fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) could predict treatment outcome of regorafenib in metastatic colorectal cancer (mCRC).

Methods

Previously treated refractory mCRC patients were enrolled into a prospective biomarker study of regorafenib. For this sub-study, the results of FDG PET/CT scans at baseline and after two cycles of treatment were analyzed. Various metabolic parameters obtained from PET images were analyzed in relation to treatment outcome.

Results

A total of 40 patients were evaluable for PET image analysis. Among various PET parameters, total lesion glycolysis (TLG) measured in the same target lesions for RECIST 1.1 analysis were the most significant in predicting prognosis, with the lowest p-value observed in TLG calculated using the margin threshold of 40 % (TLG40 %). Further analysis using TLG40 % showed significantly longer overall survival (OS) in patients with lower baseline TLG40 % (<151.8) (p = 0.003, median 14.2 vs. 9.1 months in <151.8 and ≥151.8, respectively). Patients showing higher decrease in TLG40 % after treatment showed significantly longer progression-free survival (PFS) (p = 0.001, median 8.0 vs. 2.4 months in %ΔTLG40 % < −9.6 % and ≥ −9.6 %, respectively) and OS (p = 0.002, median 16.4 vs. 9.1 months in %ΔTLG40 % < −9.6 % and ≥ −9.6 %, respectively). The same cutoff could discriminate patients with longer survival among the patients who were under the stable disease category according to RECIST 1.1 (median PFS 8.4 vs. 6.8 months, p = 0.020; median OS 18.3 vs. 11.5 months, p = 0.049).

Conclusion

Measurement of TLG can predict treatment outcome of regorafenib in mCRC.

Keywords

Metastatic colorectal cancer Regorafenib Fluorine-18 fluorodeoxyglucose positron-emission tomography Biomarker 

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Yoojoo Lim
    • 1
  • Ji-In Bang
    • 2
  • Sae-Won Han
    • 1
    • 3
  • Jin Chul Paeng
    • 2
  • Kyung-Hun Lee
    • 1
  • Jee Hyun Kim
    • 4
  • Gyeong Hoon Kang
    • 5
  • Seung-Yong Jeong
    • 6
  • Kyu Joo Park
    • 6
  • Tae-You Kim
    • 1
    • 3
    • 7
  1. 1.Department of Internal MedicineSeoul National University HospitalSeoulSouth Korea
  2. 2.Department of Nuclear MedicineSeoul National University HospitalSeoulSouth Korea
  3. 3.Cancer Research InstituteSeoul National University College of MedicineSeoulSouth Korea
  4. 4.Department of Internal MedicineSeoul National University Bundang HospitalGeyonggi-doSouth Korea
  5. 5.Department of PathologySeoul National University HospitalSeoulSouth Korea
  6. 6.Department of SurgerySeoul National University HospitalSeoulSouth Korea
  7. 7.Department of Molecular Medicine & Biopharmaceutical Sciences, Graduate School of Convergence Science and TechnologySeoul National UniversitySeoulSouth Korea

Personalised recommendations